Akari TX

NEW YORK and LONDON, September 10, 2020 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …

[Read more...] about Akari Therapeutics to Participate in Two September Virtual Investor Conferences

Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and BrazilProposed multi-center U.S. randomized clinical …

[Read more...] about Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia

Phase III randomized placebo-controlled study in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of complete disease remission on …

[Read more...] about Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan

NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a …

[Read more...] about Akari Therapeutics Announces Appointment of Chief Financial Officer